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An 81-year-old woman was referred for NSTEMI
complicated by cardiogenic shock. Urgent invasive
assessment revealed a subtotal left anterior descend-
ing artery (LAD) stenosis, severe aortic stenosis
(mean gradient 60 mmHg, aortic valve area
0.5 cm2), decreased left ventricular (LV) function
[left ventricular ejection fraction (LVEF) 49%], grade
3+ mitral regurgitation (MR), and severe pulmonary
hypertension. In view of her critical situation, acute
LAD–percutaneous coronary intervention and
aortic valvuloplasty were performed with subsequent
marked clinical improvement. Yet, she remained in
NYHA class III. Given her critical condition, the like-
lihood of double valve operation and high predicted
30-day mortality (log EuroSCORE 74%, STS 30%),
there was interdisciplinary consensus for catheter-
based strategy, primarily treating the aortic stenosis
possibly improving functional MR. Three weeks
after the acute event, she underwent trans-femoral
aortic valve implantation. However, despite an excel-
lent technical result, LVEF and MR did not improve
and she required 3 weeks ICU with intravenous cat-
echolamines and diuretics administration. As severe
MR and severe pulmonary hypertension persisted,
we opted for percutaneous mitral valve repair (Figure). One MitraClipw was successfully implanted between segment A2 and P2
with an MR reduction to grade 1+ and a drop in mean left atrial pressure from 31 to 19 mmHg.
One week after percutaneous MR repair, she was discharged in stable conditions. Eight months after, the patient has remained in
NYHA class I, whereas LV function remained stable (LVEF 55%).
At the best of our knowledge, this is the first report of a double cardiac valve intervention, performed solely by trans-femoral
access. The presented case confirms improvement in trans-catheter valve interventions enabling the treatment of high-risk patients
not suitable for open-heart surgery.
Figure. Echocardiography during MitraClip implantation. Panel A: open clip in mitral position (red arrow). Edwards 23 mm
prosthesis in aortic position (yellow arrows). Panel B: closed MitraClip after implantation in definitive mitral position. The
middle panels show the Color duplex examination of the mitral valve before (Panel C) and after (Panel D) successful implan-
tation of one MitraClip. The bottom panels show the haemodynamic curves in the left atrium before (Panel E) and after
MitraClip implantation (Panel F).
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